InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm

InspireMD, Inc.

2026-Q1 EPS reported -$0.16 revenue$3,398,000

Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.
GAAP gross profit $0.7M (20.2% margin); adjusted gross profit $1.2M (34.1%) excluding $0.5M impairment charge.
Voluntary recall of CGuard Prime 135 cm; expected costs $700K returns + $650K inventory/remediation.
FDA approved IDE for CGUARDIANS III trial of SwitchGuard NPS; CGuard Prime 80 cm TCAR approval expected H2 2026.
Original CGuard FDA approval anticipated Q3 2026; over 625 cumulative procedures with CGuard Prime since launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

InspireMD, Inc. reported first quarter ended March 31, 2026 results: revenue $3.4 million, net income $13.7 million, EPS $0.16 per basic and diluted share.

Period: first quarter ended March 31, 2026
Revenue: $3.4 million
Net income: $13.7 million
EPS: $0.16 per basic and diluted share
Result: reported results

Exact text from the filing

expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for use in

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.